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In this report, wedescribe the useofextracorporeal photochemotherapy in thetreatment oftwo
patients with rapidly advancing progressive systemic sclerosis. Both patients experienced
improvement in the cutaneous as well as the systemic manifestations of their disease while
undergoing therapy. The potential therapeutic mechanisms are discussed.
The ability to ameliorate or prevent autoimmune disease by the in vivo administra-
tion of lethally damaged syngeneic pathogenic T-cell clones is well established in
animal models [1]. In this regard, recent observations by Khavari and colleagues [2]
have demonstrated that one of the most effective means of prophylaxis against the
development of murine experimental allergic encephalitis has been to inoculate
animals with myelin basic protein-specific T-cell clones that have initially been
photoinactivated with 8-methoxypsoralen (8-MOP) and ultraviolet A radiation. With
the introduction ofextracorporeal photochemotherapy into theclinic for the treatment
of cutaneous T-cell lymphoma (CTCL) [3], this basic therapeutic strategy, which
undertakes the extracorporeal photoinactivation of peripheral blood leukocytes using
8-MOP and ultraviolet A, followed by their reinfusion, is now available for the
treatment of human autoimmune diseases. In light of this fact, it is noteworthy that a
number of patients, who exhibited concomitant manifestations of both CTCL and
autoimmune disease and were treated with extracorporeal photochemotherapy at our
center, experienced marked improvement in their autoimmune phenomenon during the
treatment. These clinical observations resulted in the genesis ofseveral pilot studies to
assess the efficacy ofextracorporeal photochemotherapy in the treatment ofaggressive
autoimmune disease. One protocol has included the treatment of corticosteroid and
immunosuppressive drug-resistant pemphigus vulgaris in an effort to determine if
extracorporeal photochemotherapy could produceclinical improvement, which was not
previously possible with potent immune-suppressing medications. (Refer to the article
by Rook and colleagues which follows this.) A second pilot study was initiated to
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examine the effects of extracorporeal photochemotherapy on the evolution of
progressive systemic sclerosis. In this report, we describe the beneficial effect of
extracorporeal photochemotherapy on the cutaneous as well as the systemic manifesta-
tions ofscleroderma in the two patients participating in this initial study. These results
have formed the basis for the initiation ofa larger multi-center clinical trial.
TREATMENT PROCEDURE
The treatment of the patients was accomplished using the UVAR photopheresis
system (Therakos, West Chester, PA) in a manner similar to that which has been
previously described for cutaneous T-cell lymphoma [3]. Briefly, two hours following
the ingestion of 0.6 mg of 8-MOP per kilogram of body weight, patients underwent a
discontinous leukapheresis procedure with subsequent exposure ofremoved leukocytes
to ultraviolet A radiation. During the procedure, approximately 240 ml of leukocyte-
enriched blood was mixed with 300 ml of the patients' plasma, and 200 ml of sterile
normal saline. The final buffy coat preparation contained an estimated 25-50 percent
of the total peripheral blood leukocyte compartment and had a hematocrit ranging
from 2.5 to 8 percent. The buffy coat then passed as a 1 mm film through a sterile
cassette, permitting a 270-minute exposure to ultraviolet A, yielding an average
exposure per lymphocyte of 2 j/cm2. Following exposure of the cells to ultraviolet A,
the buffy coat was returned to the patient. During the initial phases of therapy, the
patients received the treatment on each of two successive days at four-week intervals.
If, after three treatments, improvement was not observed, therapy was increased to two
treatments on successive days at two-week intervals.
PATIENT SELECTION AND EVALUATION
The two patients selected for treatment had the diagnosis of progressive systemic
sclerosis made by a combination ofclinical and histological criteria, which included the
evaluation ofa skin biopsy. Both patients were chosen for this pilot study as a result of
their unusually rapid progression of skin thickening to involve a majority of their
cutaneous surface area. Clinical evaluations of skin thickening before and during
therapy were performed independently by at least two examining physicians.
CASE HISTORY
Patient I
This patient was a 60-year-old male who was in excellent health until April 1986,
when he developed Raynaud's phenomenon and arthralgias. In September 1986, he
noted the development of skin swelling and tightness on his upper extremities and
trunk and a diagnosis of progressive systemic sclerosis was made. Nifedipine 10 mg
three times daily was started. By November 1986, the skin tightening had progressed
rapidly to involve all areas except the distal lower extremities. Finger mobility was
markedly decreased; 250 mg D-penicillamine daily was added. In March 1987, the
patient was referred for potential treatment with extracorporeal photochemotherapy.
At that time, marked skin tightening and sclerosis ofhands, forearms, abdomen, chest,
and legs was observed (Fig. IA, dated March 25, 1987). Decreased finger mobility and
grip were evident at this time. All fingertips exhibited necrotic ulcerations. Pulmonary
function testing revealed a carbon monoxide diffusing capacity which was 68 percent
of the expected normal. An upper gastrointestinal series demonstrated esophageal
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Patient I
y/25187 4/11/88 5/16/88 8/18/88 2/6/89
Patient 2
11/87 5/9/8 8/23/88 1/23/89 3/27/89 5/17/89
FIG. 1. A. Progress of skin thickening in patient I during treatment with extracorporeal
photochemotherapy. Areas in black indicate skin thickening on physical examination. B. The
course ofskin thickening in patient 2 during extracorporeal photochemotherapy treatment.
hypomotility. A urine analysis revealed 3+ protein, and a 24-hour urine collection
contained 1,300 mg ofprotein. Red cell fragments were present on the peripheral blood
smear, indicative of microangiopathic hemolytic anemia. Blood urea nitrogen and
serum creatinine were normal. On March 27, 1987, the patient was started on
extracorporeal photochemotherapy. After one month, the patient felt symptomatically
improved. At the third cycle, red cell fragments were no longer detectable on the
peripheral blood smear, and repeat urinalysis revealed the absence ofurinary protein.
The D-penicillamine was discontinued in August 1987. By the ninth cycle of therapy
(December 1987), the Raynaud's phenomenon was no longer present and all digital
ulcers had healed, permitting discontinuation of nifedipine. By April 11, 1988, aside
from a minor degree ofskin thickening on the forearms, hands, and mid-abdomen, the
skin examination had returned to normal. At this time, repeat pulmonary function
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testing revealed a carbon monoxide-diffusing capacity that had improved to 96 percent
of the expected normal value. A 24-hour urine collection demonstrated less than 300
mg ofprotein. The patient elected to decrease the frequency of treatments from every
four weeks to every six weeks. On May 16, 1988, he was noted to have new skin
thickening on a large area of the left anterior chest (Fig. IA). Treatments were
reinstituted on an every-four-week basis. Except for mildsclerodactylia, all skin
thickening has resolved, and, at present (June 1989), there are no other demonstrable
subjective or objective clinical criteria consistent with the original diagnosis of
progressive systemic sclerosis.
Patient 2
This patient was a 42-year-old female who was well until late 1985 when she noted
the onset of Raynaud's phenomenon. In early 1987, skin thickening on the hands and
distal legs was first noted. D-penicillamine 250 mg daily was begun. Cutaneous
thickening progressed rapidly to involve arms, face, trunk, and legs (Fig. I B).
D-penicillamine was increased to 750 mg daily by July 1987. At this time, the patient
noted decreased salivation, dry eyes, marked weakness of her arms and legs, decreased
sweating, hair loss, and loss of weight. The patient was started on extracorporeal
photochemotherapy on November 30, 1987. A creatine phosphokinase obtained at that
time was 570 (upper limit ofnormal, 150). By January 1988, numerous flaccid vesicles
erupted on the extremities, and prednisone 40 mg daily was added and the D-
penicillamine was discontinued. The vesiculation responded promptly, and the predni-
sone was tapered and discontinued over a16-week period. At the fourth cycle of
therapy (March 10, 1988), no improvement in the skin thickening was noted, and the
treatment frequency was increased to every two weeks for two cycles and then to every
three weeks. By May 9, 1988 (Fig. IB), significant skin softening was observed on the
upper chest and mid-abdomen. Continuous improvement occurred during the next
several months. A repeat creatine phosphokinase in July of 1988 was less than 20 units,
which correlated with improved strength. The patient indicated that her hypohidrosis
and xerostomia had improved and that she felt an overall improvement in her sense of
well-being. During the winter of 1988, she indicated that her Raynaud's phenomenon
had improved. During early 1989, the skin on her abdomen and upper arms slowly
recommenced to thicken. In March 1989, despite encouragement to return to an
every-two-week course oftherapy, she elected to discontinue extracorporeal photoche-
motherapy. Since March of 1989, her general condition as well as her skin thickening
has continued to deteriorate.
DISCUSSION
The results of this pilot study demonstrated the improved clinical course of two
patients with progressive systemic sclerosis while undergoing extracorporeal photoche-
motherapy (Table 1). One of the patients is currently experiencing a sustained
complete remission while remaining on an every-four-week regimen. The clinical
improvement in ourpatients was not restricted to the cutaneous manifestations of their
disease, as patient I had complete normalization ofhis pulmonary and renal abnormal-
ities and disappearance of the microangiopathic hemolysis as well as the Raynaud's
phenomenon. Patient 2, although concomitantly on a short course of low-dose
prednisone, as well as D-penicillamine, experienced improvement in her myopathy, her
Sjogren's-like symptoms, and her Raynaud's phenomenon. It is noteworthy that our
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TABLE 1
Clinical Manifestations ofProgressive Systemic Sclerosis Before and During
Treatment with Extracorporeal Photochemotherapy
Clinical Signs
Patient Before Treatment During Treatment
Skin thickening Resolved
Proteinurea Resolved
Microangiopathic hemolysis Resolved
Raynaud's phenomenon Resolved
Decreased DLCO Normalized
2 Skin thickening Improved
Myositis Resolved
Xerostomia Resolved
Raynaud's phenomenon Improved
Hypohydrosis Resolved
beneficial results were obtained with virtually no side affects attributable to extracor-
poreal photochemotherapy. Throughout the course of treatment, the only adverse
event related to therapy was a single occurrence of mild hypotension in patient 2.
Moreover, we failed to document clinical evidence of immune suppression. Most
important, during the past five years at our institution, we have not observed any
long-lasting harmful effects of extracorporeal photochemotherapy in any of our
treatment populations.
The beneficial effects ofextracorporeal photochemotherapy on the course ofour two
patients with progressive systemic sclerosis complement our clinical observations
regarding the effects of this treatment on other autoimmune diseases. We have
previously described the marked improvement of patients with immunosuppressive
drug-resistant pemphigus vulgaris (see the article by Rook et al. in this issue).
Currently three offour patients with pemphigus vulgaris have experienced long-lasting
remissions induced by extracorporeal photochemotherapy and are currently off
therapy. We have also observed improvement in all aspects of disease expression in a
patient with collagen vascular disease overlap syndrome with features of systemic
lupus erythematosus, Sjogren's syndrome, and polymyositis. Finally, a patient with an
IgG-associated autoimmune hemolytic anemia, which occurred concomitantly with
CTCL, experienced a significant steroid-sparing effect when extracorporeal photoche-
motherapy was initiated for the treatment of the lymphoma. Thus, it appears that
extracorporeal photochemotherapy may provide promise for the future treatment of
autoimmune diseases.
At present, the use of extracorporeal photochemotherapy is in its infancy as a
therapeutic tool for autoimmune disease. Therefore, the optimal regimens for each
treatment-responsive disease will be determined as experience with current and future
clinical trials broadens. In this regard, our observations with pemphigus vulgaris and
progressive systemic sclerosis indicate that treatment cycles administered on an
every-two-week basis may be superior to monthly treatments for individuals with
rapidly progressive disease. Similarly, while therapeutic responses may be obtained in
many cases with monthly treatments, more frequent regimens need to be considered
for those who fail to respond at this frequency of treatment.
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Another issue that is relevant to the maximization of the benefit of extracorporeal
photochemotherapy relates to the concomitant use of other pharmacological agents
that may have activity against the "targeted" autoimmune disease. As an example,
although patient 2, with progressive systemic sclerosis, improved clinically while on
twice-monthly extracorporeal photochemotherapy, her D-penicillamine administra-
tion overlapped with this therapy, and she was also started on a modest dose of
prednisone just preceding her improvement. Thus, in her case, D-penicillamine and
prednisone used together with extracorporeal photochemotherapy may have played a
prominent role in her partial recovery. Aside from prednisone and D-penicillamine,
other agents which directly inhibit collagen synthesis [4], such as gamma interferon,
may ultimately be demonstrated to enhance the benefit ofextracorporeal photochemo-
therapy in the treatment ofprogressive systemic sclerosis.
The precise therapeutic mechanisms underlying the effect of extracorporeal photo-
chemotherapy on autoimmune disease have not been clearly delineated. Data derived
from clinical observations as well as animal models support several potential modes of
action. Khavari et al. [21 and Perez and colleagues [5], employing murine models of
experimental allergic encephalitis and cutaneous allograft rejection, respectively, have
each developed evidence that a clonotypic immune response occurs when specific
pathogenic T cells are first treated in vitro with 8-MOP and ultraviolet A radiation,
and then reinfused into syngeneic animals. One of the characteristics of this immune
response is the generation of a clone-specific suppressor T-cell response [2,5], which
inhibits the proliferation ofthe pathogenic Tcell. Similarly, patients with autoimmune
disease who have experienced clinical improvement while receiving extracorporeal
photochemotherapy sustain an increase in the numberofperipheral blood lymphocytes
which phenotypically express features of suppressor T cells [Rook AH, et al:
unpublished results]. Evidence from studies of CTCL patients further supports the
importance ofthe suppressor-cytotoxic population ofT cells in the clinical response to
extracorporeal photochemotherapy. In this respect, we have demonstrated a striking
relationship between the absolute numbers of circulating CD8+ T cells and the
ultimate ability to develop substantial disease regression while receiving extracorpor-
eal photochemotherapy [Rook AH, Nahass GT: unpublished results]. Thus, in the case
ofprogressive systemic sclerosis, which is characterized by an increase in the numbers
of activated helper T cells at sites of heightened collagen production [6,7] a CD8+
suppressor T-cell response may be generated which "dampens" the activity of the
"autoreactive" helper T lymphocytes.
Extracorporeal photochemotherapy has been established as an effective form of
treatment for CTCL. In addition, the initial success of extracorporeal photochemo-
therapy in the treatment ofa small numberofindividuals with pemphigus vulgaris and
progressive systemic sclerosis has led to the development of carefully planned clinical
trials for a variety ofautoimmune diseases. These studies will permit a further analysis
of the potential promise ofthis novel form ofimmunotherapy.
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